Table 3. Intensity of solicited adverse events (AE) following the COVID-19 inactivated vaccine (CoronaVac) in the elderly, according to dose. Sao Paulo, 2021.
| Grade 1 / Mild | Grade 2 / Moderate | Grade 3 / Intense | Grade 4 / Serious | |
|---|---|---|---|---|
|
| ||||
| Does not interfere with daily activities | Interferes little with daily activities | Prevents daily activities; requires medical assistance | Potentially life-threatening; requires hospitalization or emergency room visit | |
| 1 st dose (n) | ||||
| Local pain (13) | 9 | 4 | 0 | 0 |
| Erythema (2) | 2 | 0 | 0 | 0 |
| Swelling (2) | 2 | 0 | 0 | 0 |
| Induration (1) | 1 | 0 | 0 | 0 |
| Pruritus (3) | 3 | 0 | 0 | 0 |
| All local AE after 1 st dose (21) | 17 (80.95%) | 4 (19.05%) | 0 | 0 |
| Headache (6) | 2 | 3 | 1 | 0 |
| Fatigue (9) | 5 | 3 | 1 | 0 |
| Myalgia (5) | 3 | 1 | 1 | 0 |
| Arthralgia (2) | 0 | 2 | 0 | 0 |
| Chills (4) | 4 | 0 | 0 | 0 |
| Nausea (5) | 3 | 2 | 0 | 0 |
| Vomiting (2) | 1 | 0 | 1 | 0 |
| Diarrhea (6, 1 NI) | 4 | 1 | 0 | 0 |
| Anorexia (3) | 3 | 0 | 0 | 0 |
| Pruritus (6) | 5 | 1 | 0 | 0 |
| All systemic AE after 1 st dose (48, 1 NI) | 30/47 (63.83%) | 13/47 (27.66%) | 4/45 (8.51%) | 0 |
|
| ||||
| 2 nd dose (n) | ||||
| Pain (5) | 4 | 1 | 0 | 0 |
| Induration (1) | 1 | 0 | 0 | 0 |
| All local AE after 2 nd dose (6) | 5/6 | 1/6 | 0 | 0 |
| Fever (2; 1 NI) | 1 | 0 | 0 | 0 |
| Headache (6) | 2 | 3 | 1 | 0 |
| Fatigue (8) | 5 | 3 | 0 | 0 |
| Myalgia (10) | 5 | 5 | 0 | 0 |
| Chills (2) | 2 | 0 | 0 | 0 |
| Nausea (6) | 3 | 2 | 1 | 0 |
| Vomiting (2) | 0 | 1 | 1 | 0 |
| Diarrhea (3; 2 NI) | 1 | 0 | 0 | 0 |
| Anorexia (7; 1 NI) | 6 | 0 | 0 | 0 |
| Pruritus (3) | 3 | 0 | 0 | 0 |
| All systemic AE after 2 nd dose (49, 4 NI) | 28/45 (62.22%) | 14/45 (31,11%) | 3/45 (6.67%) | 0 |
NI = not informed.